IL-17 in Systemic Lupus Erythematosus
| Title: | IL-17 in Systemic Lupus Erythematosus |
| Author: |
Crispín, José C.; Tsokos, George C.
Note: Order does not necessarily reflect citation order of authors. |
| Citation: | Crispín, José C., and George C. Tsokos. 2010. IL-17 in systemic lupus erythematosus. Journal of Biomedicine and Biotechnology 2010: 943254. |
| Full Text & Related Files: |
2850519.pdf (522.5Kb; PDF) 
|
| Abstract: | IL-17 is a cytokine with powerful proinflammatory activity. Production of IL-17 is abnormally increased in patients with systemic lupus erythematosus (SLE), a multiorgan chronic autoimmune disease. In patients with SLE, CD3+CD4−CD8− (double negative) T cells are an important source of IL-17. IL-17 produced by double negative and CD4 T cells participates in the pathogenesis of the disease. IL-17-producing T cells are present in the kidneys of patients with lupus nephritis. IL-17 increased production in patients with SLE can amplify the immune response by increasing target organ inflammation and damage and by augmenting the production of antibodies by B cells. |
| Published Version: | doi:10.1155/2010/943254 |
| Other Sources: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850519/pdf/ |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:4739309 |
This item appears in the following Collection(s)
-
HMS Scholarly Articles [4046]
Contact administrator regarding this item (to report mistakes or request changes)
